Navigating the Basics of NVO – A Stock Analysis

By Emilio Sanchez • Friday, December 20 10:11 • Permanent Link

Novo Nordisk A/S logged a -18.9% change during today's morning session, and is now trading at a price of $83.91 per share. The S&P 500 index moved -0.0%. NVO's trading volume is 18,621,378 compared to the stock's average volume of 5,321,766.

Novo Nordisk A/S trades -36.54% away from its average analyst target price of $132.23 per share. The 10 analysts following the stock have set target prices ranging from $80.187805 to $159.65152, and on average have given Novo Nordisk A/S a rating of buy.

Anyone interested in buying NVO should be aware of the facts below:

Novo Nordisk A/S's current price is -15.7% below its Graham number of $99.49, which implies the stock has a margin of safety
Novo Nordisk A/S has moved 0.7% over the last year, and the S&P 500 logged a change of 23.4%
Based on its trailing earnings per share of 2.98, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 28.2 while the S&P 500 average is 29.3
NVO has a forward P/E ratio of 20.6 based on its forward 12 month price to earnings (EPS) of $4.07 per share
Its Price to Book (P/B) ratio is 3.1 compared to its sector average of 3.53
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Based in Bagsvaerd, the company has 71,880 full time employees and a market cap of $391.1 Billion. Novo Nordisk A/S currently returns an annual dividend yield of 9.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.